Rochester, NY - Researchers are calling for beta-blocker treatment for patients with intermittent claudication, arguing that it is "old school" to avoid them in this high-risk group [1]. The new study ...

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its ...

The pathophysiology of intermittent claudication is complex as it involves both a reduction in blood flow to peripheral tissues as well as changes in the metabolic function of skeletal muscle, caused ...

Researchers at King's have been awarded £2.1m in funding to take a new regenerative, cell-based therapy for leg pain caused by reduced blood flow to ...

PAD patients with claudication undergoing peripheral vascular interventions (PVIs) in contemporary practice have a 4% risk of amputation within 4 years, with higher risk seen among those ...

* Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage: ...